Return to homepagePandemic Pact

Clinical Development of COVID-19 Therapeutics

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93023C00052-P00001-9999-1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2023
    2026

  • Known Financial Commitments (USD)

    $1,300,776

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    STANLEY WANG

  • Research Location

    United States of America

  • Lead Research Institution

    ALIGOS THERAPEUTICS, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Other

  • Occupations of Interest

    Unspecified

Abstract

To support the advanced development of candidate therapeutics for a virus covered under the Antiviral Program for Pandemics. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment. Efforts include a Phase I clinical trial in renal and hepatic impaired patients.